<DOC>
	<DOCNO>NCT00522795</DOCNO>
	<brief_summary>Neoadjuvant Paclitaxel Poliglumex ( PPX ; CT-2103 ) , Cisplatin Radiation Esophageal Cancer : A Phase II Trial . ( CTI # X64001</brief_summary>
	<brief_title>Neoadjuvant Paclitaxel Poliglumex , Cisplatin Radiation Esophageal Cancer : A Phase II Trial ( CTI # X64001 )</brief_title>
	<detailed_description>32 patient esophageal gastroesophageal junction cancer receive Radiation:50.4 Gy 180cGy fraction/day 28 treatment Paclitaxel Poliglumex ( PPX ) Cisplatin weekly time 6 follow surgery .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients require pathologically confirm adenocarcinoma squamous cell carcinoma esophagus gastroesophageal junction Patients may celiac adenopathy There must evidence distant organ metastases No prior chemotherapy radiation esophageal cancer Patients must &gt; 18 year age , non pregnant Patients must ANC &gt; 1,500/ul , platelet &gt; 100,000/ul , creatinine &lt; 2.0 bilirubin &lt; 1.5 x ULNECOG performance status 01 . Female patient , must either child bear potential negative pregnancy test within 14 day start study treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Pregnant lactating female eligible No contraindication esophagectomy Signed informed consent Active uncontrolled infection Patients must coexistent medical condition would preclude protocol therapy . Any concurrent chemotherapy indicate study protocol investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Esophageal Cancer</keyword>
</DOC>